Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial-Reference-Cited by-同舟云学术

Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial

Published:2021-07-21 Issue:8 Volume:8 Page:1610-1621
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann. Clin. Transl. Neurol.

Author:

Schultz Timothy J.¹^ORCID,Thomas Anne²,Georgiou Paul³,Juaton Mahasen S.¹,Cusack Lynette¹,Simon Lorraine³,Naidoo Kerisha⁴,Webb Kevin⁵,Karnon Jonathan⁶,Ravindran Janakan⁵

Affiliation:

1. Adelaide Nursing School University of Adelaide Adelaide South Australia Australia

2. Post Op Care at Home (Pty Ltd) Adelaide South Australia Australia

3. Medical Day Treatment Unit Royal Adelaide Hospital Adelaide South Australia Australia

4. Biogen Australia and New Zealand Sydney New South Wales Australia

5. Neurology & Stroke Unit Royal Adelaide Hospital Adelaide South Australia Australia

6. College of Medicine and Public Health Flinders University Adelaide South Australia Australia

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.51410

Reference39 articles.

1. Practical Guidelines for Administering Natalizumab: A Nursing Perspective

2. Natalizumab adverse events are rare in patients with multiple sclerosis

3. Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy

4. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

5. Disease‐modifying treatments for multiple sclerosis – a review of approved medications

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis;Neurology and Therapy;2024-09-04

2. Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35);Multiple Sclerosis and Related Disorders;2023-05

3. Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis;Annals of Clinical and Translational Neurology;2023-02-22

4. Customer-centric product presentations for monoclonal antibodies;AAPS Open;2023-01-23